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Objectives: To evaluate the impact of retrospective drug utilization review (RDUR), 
  pharmacist’s interventions on physician prescribing, and the level of spillover effect on future 
prescriptions following the intervention.
Methods: A retrospective case–control study was conducted at a pharmacy benefits management 
company using the available prescription data from April 2004 to August 2005. RDUR conflicts 
evaluated and intervened by a clinical pharmacist served as a case group, whereas conflicts that 
were not evaluated and intervened by a clinical pharmacist served as a control group.
Results: A total of 40,284 conflicts in cases and 13,044 in controls were identified. For cases, 
32,780 interventions were considered nonrepetitive, and 529 were repetitive. There were 22,870 
physicians in cases that received intervention letters and 2348 physicians in the control group 
that would have received intervention letters during the study period. Each physician received 
on average 1.4 interventions for cases vs 3.0 for controls. Among the case physicians who 
were intervened during the study period, 2.2% (505) were involved in a repeated intervention 
vs 18.2% (428) in controls (P , 0.001), which is an eight-fold difference. The most common 
conflict intervened on in cases was therapeutic appropriateness (8277, 25.3%), and for controls 
it was drug–drug interactions (1796, 25.4%). The overall interventional spillover effect in cases 
was 98.4% vs 89.4% in controls (P = 0.01).
Conclusion: RDUR is an effective interventional program which results in decreased numbers 
of interventions per physician and provides a significant impact on future prescribing habits.
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Introduction
The introduction of pharmacy benefits management companies came about due to the need 
for a point-of-service system to adjudicate pharmacy claims in the 1980s. Over the years, 
other value-added programs such as drug usage review (DUR), generic substitution, and 
step-care protocols have been added to improve quality of medical care and control health 
care costs. According to the 2006 Novartis Pharmacy Benefit Report,1 services such as 
DUR and generic substitution are now used by over 90% of the managed care organizations 
surveyed. The use of generic substitution and DUR is now the most frequently reported 
quality and cost control measure. Specifically, the use of DUR increased over the period 
for preferred provider organizations (2003–2004, 60.9%–70.4%) and health maintenance 
organizations (2003–2004, 68.4%–74.4%). It has long been recognized that drugs are not 
frequently used to their full potential, nor according to usually accepted criteria.2,3 Since 
the majority of the prescriptions are written by physicians, their prescribing habits are 
important when considering the inappropriateness of drug use.4ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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The goals of DUR were explained by Knapp et al5 as 
the encouragement of optimal drug use and the provision 
of high-quality drug therapy as cost-effectively as possible. 
Pharmacists are frequently called upon to assess medication 
prescribing by physicians and provide the important service 
of DUR.2 The outcomes of these assessments often lead to 
improvements in cost-effective prescribing and better utiliza-
tion of limited resources.4 Although DUR is part of the vast 
majority of managed care quality assurance programs, the 
benefit of such a program has conflicting results reported in 
the literature.
A typical drug evaluation process generally entails an 
in-depth analysis of an agreed specific therapeutic group 
or groups.6 The method of analysis generally involves 
a   pharmacist screening the literature and clinical data, 
  developing and gaining agreement on practice guidelines in 
conjunction with other related departments, and evaluating 
the collected data against it.2 The results of the review will 
be presented to the prescribers along with medical literature 
and education to support the modification of their   prescribing 
behavior.2 To ensure compliance, physician prescribing 
behavior is then monitored over time. DUR is a quality 
assurance approach for the facility per se, and it involves 
the setting of criteria and standards, an assessment phase 
using a set of screening criteria, and a follow-up correctional 
phase with the prescriber.7 It comprises all aspects of drug 
treatment from the time a patient presents to a prescriber to 
the final outcome of the therapy.7
The objective of this study is to evaluate a   retrospective 
DUR (RDUR) pharmacist intervention program on   physicians 
prescribing for adult patients. This is achieved by identify-
ing the impact of intervention on physician prescribing and 
evaluating the level of spillover effect on future prescriptions 
following the intervention.
Methods
A retrospective case–control study was conducted at a 
pharmacy benefits management company (PBM) using the 
available prescription data from April 2004 to August 2005. 
The PBM has an electronic data repository that houses all 
pharmacy claims data. Pharmacy claims data is sent to an 
outside vendor, where it is evaluated against medical claims 
data and then returned to the PBM. A severity score is 
assigned to each conflict based on predetermined   criteria. 
The clinical pharmacist then evaluates those conflicts 
against evidence-based guidelines and categorizes them into 
clinically significant and clinically nonsignificant groups. 
Only 1% of all clinically significant conflicts obtained from 
available pharmacy claims data were reviewed in detail, and 
interventions were made where applicable. All the intervened 
conflicts were included in the case group for this study. 
Clinically significant conflicts which were generated by the 
RDUR software but not intervened by a clinical pharmacist 
served as the control group. In the control group, pharmacist 
interventions were not implemented but were treated as 
though the intervention was implemented for the study 
purposes. For the purposes of this study, all case physicians 
who were intervened with in the study were eliminated from 
the control groups.
A conflict occurs when the prescription does not meet 
RDUR-established criteria (eg, drug–drug interactions, 
therapeutic appropriateness). A nonrepeated intervention 
is an intervention with a physician for different patients on 
a   specific criterion that can occur multiple times within a 
60-day period of the first intervention. For the purpose of 
this study, the nonrepetitive intervention is considered one 
  intervention no matter how many times it occurs within 
60 days. A repeated intervention is an intervention with a 
physician for different patients on a specific criterion that 
occurs 60 days after the first intervention. The physician 
spillover effect evaluates the impact of past interventions on 
prescribers for the future care of the patients. The interven-
tional spillover effect evaluates the rate of repetitive interven-
tions that occur based on the total number of nonrepetitive 
interventions.
The following data collected for the study included 
patient demographics, pertinent prescription information 
(such as drug name, date of prescription), physician ID, and 
intervention details. Data analyses were performed using 
SPSS Statistics software (v 11.5; IBM Corporation, Somers, 
NY). The case group was compared with the control group 
for spillover effect during the study period. A descriptive 
analysis of the case group was performed.
Results
In the case group, 40,284 conflicts were identified and of 
those, 32,780 interventions were considered nonrepetitive 
and 529 were repetitive. In the control group, 13,044 con-
flicts were identified, and of those, 7069 interventions were 
considered nonrepetitive and 748 were repetitive. The total 
of repetitive and nonrepetitive interventions is less than the 
total number of conflicts, because those conflicts that occur 
within 60 days after the first intervention were excluded 
from the analysis.
There were 22,870 physicians in cases that received 
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that would have received intervention letters during the study 
period. Each physician received on average 1.4 interventions 
for cases vs 3.0 in controls. Case physicians (14,210, 62.1%) 
were more likely to receive one nonrepetitive intervention 
compared with controls, whereas in other categories, control 
physicians were more likely to receive higher numbers of 
nonrepetitive interventions (Table 1).
The most common conflict intervened on in cases was 
therapeutic appropriateness (8277, 25.3%), and for controls 
it was drug–drug interactions (1796, 25.4%). Other conflict 
types were very similar between cases and controls (Table 2). 
The rate of repeated interventions was lower in cases vs 
  controls. Of these 22,870 physicians who were intervened dur-
ing the study period, 2.2% (505) were involved in a repeated 
intervention vs 18.2% (428) in controls (P , 0.001). The 
actual physician spillover effect was 16% (2.2%–18.2%).
The overall interventional spillover effect was also greater 
in cases vs controls. There were 32,780 nonrepeated interven-
tions in cases vs 7069 in controls. The number of repetitive 
interventions in cases was 529 (1.6%) and in controls was 
748 (10.6%). The interventional spillover effect in cases 
was 98.4% vs 89.4% in controls (P = 0.01). The actual 
interventional spillover effect identified in this case–control 
study was 9.0%.
Discussion
To our knowledge, this study is the first of its kind in research 
methodology to be carried out to evaluate the physician 
spillover effect in a large RDUR program. Our hypothesis 
was that the interventions made by the RUDR pharmacists 
would have an impact on future physician prescribing, and 
the intervention spillover effect would significantly improve 
vs the control group. The methodology used to achieve this 
objective was a case–control study.
We found that the physician spillover effect was greater in 
cases compared with controls. A physician who was part of a 
case group was eight times less likely to receive the repeated 
interventions during the study period than a physician in the 
control group. The probable cause of high physician spillover 
effect in cases was the continuous pharmacist educational 
interventions during and prior to the study period. The influ-
ence of the pharmacist on physician prescribing reduces 
the need for continuous intervention on the same criteria. 
The control group did not show a similar improvement in 
the need for the repeated interventions.
The overall interventional spillover effect was signifi-
cantly higher in cases compared with controls. The number 
of repeated interventions was 67% higher per physician in the 
controls in addition to an increase in the number of physicians 
that were intervened, as discussed previously. The differential 
effect between the cases and controls can only be attributed 
to the lessons learned from the previous interventions.
A previous study by Hennessy et al8 on RDUR prescribing 
errors and clinical outcomes was unable to identify an effect 
of RDUR on the rate of exceptions or clinical outcomes. 
However, there are many limitations to their study such as 
the fact that they did not include a comparison control group. 
The study only took into consideration drug–drug, drug–
disease, and   duplication criteria. There was much variation 
in the rate of alerts based on the exceptions generated through 
their DUR software. Their clinical outcomes assessment is 
based on the rate of exceptions, and not the rate of alerts, 
sent to the physician. Also, they did not identify any false 
positive exceptions which could have impacted the outcome 
of the study. Finally, they did not check any individualized 
physician prescribing behavior.
This study has a number of strengths, such as studying the 
impact of RDUR interventions on actual physician prescribing, 
looking at all therapeutic categories, and comparing the inter-
ventional effect in cases vs controls. All conflicts were assigned 
a severity score, and interventions were only made in patients 
with high severity scores that were considered clinically 
  significant. The control group was matched to the case group 
in terms of severity score. To eliminate any bias, we removed 
all case physicians from the control group.   Additionally, our 
analysis was based on actual interventions sent to the physi-
cian, which directly correlates to the outcomes.
Table 1 number of nonrepetitive interventions per prescriber
Number of nonrepetitive  
interventions
Cases Controls
1 14,210 (62.1%) 930 (39.6%)
2–5 7985 (34.9%) 1088 (46.3%)
6–10 550 (2.4%) 249 (10.6%)
11–20 111 (0.5%) 78 (3.3%)
20+ 14 (0.1%) 3 (0.1%)
Table 2 Nonrepetitive conflicts intervened
Nonrepetitive  
conflict type
Cases  
(N = 32,780)
Controls  
(N = 7069)
Therapeutic appropriateness 8277 (25.3%) 1117 (15.8%)
Therapeutic duplication 5641 (17.2%) 1096 (15.5%)
Underuse precaution 6076 (18.5%) 1057 (15.1%)
Drug–drug interaction 5823 (17.8%) 1796 (25.4%)
high dose 2703 (8.2%) 684 (9.7%)
Drug–disease precaution 2347 (7.2%) 504 (7.1%)
Overuse precaution 1913 (5.8%) 815 (11.5%)ClinicoEconomics and Outcomes Research
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We did not correlate our interventions with medical 
outcomes such as hospitalizations. Also, we did not check 
whether the physician changed the prescription based on 
the recommendation of the pharmacist. We did not have 
any baseline data prior to the implementation of the RDUR 
program in the case and control group. Another limitation to 
this study is that we assumed that any intervention made on 
behalf of a patient is the reason that the intervention does not 
occur again. It could be that the reason a repeated interven-
tion does not occur is that the same factors that caused the 
first intervention did not occur again, for example a specific 
drug–drug interaction.
These results indicate that continuous educational 
interventions by pharmacists can have a significant impact 
on physician prescribing. Future research should focus on 
  correlating the interventional spillover effect to clinical 
health outcomes such as hospitalization and emergency 
room visits. An improvement in health outcomes should lead 
to reduction in morbidity and mortality in this population. 
Other areas of research include pharmacoeconomics   analysis 
to determine the cost–benefit of these RDUR programs. 
A previous study focused on the rates of hospitalizations 
per exception.8 However, it may be more appropriate to look 
at the direct impact of these RDUR programs by measur-
ing the hospitalizations avoided in the specific populations 
studied and then extrapolating that to a similar population. 
Reducing hospitalization even a small amount may justify 
  implementing these programs.
In conclusion, our case–control study which analyzed 
the impact of RDUR pharmacist interventions on physician 
prescribing found that physician spillover effect in cases 
was eight times higher than controls. On average, each case 
physician received 67% less interventions compared with 
controls.
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